articleTop 10% cited

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

Human Pathology · 1992 · Vol. 23(9) · pp. 974–979

D. Craig Allred✉(The University of Texas Health Science Center at San Antonio)Gary M. Clark(Beth Israel Deaconess Hospital)Rafael Molina(The University of Texas Health Science Center at San Antonio)Atul K. Tandon(Beth Israel Deaconess Hospital)Stuart J. Schnitt(The University of Texas Health Science Center at San Antonio)Kennedy W. Gilchrist(University of Wisconsin–Madison)C. Kent Osborne(The University of Texas Health Science Center at San Antonio)Douglass C. Tormey(Hospital Clínic de Barcelona)William McGuire(University of Wisconsin–Madison)

View via DOI Publisher page

HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Cancer Cells and MetastasisBreast cancerHER2/neuIn situOncologyInternal medicinePathologyCancerBiologyMedicineCancer research

MeSH terms

BreastBreast NeoplasmsCarcinoma in SituCarcinoma, Intraductal, NoninfiltratingFemaleHumansHyperplasiaNeoplasm InvasivenessPrognosisProto-Oncogene ProteinsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2

Citations

409

FWCI

11.41

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

The HER‐2/ <i>neu</i> Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy